Charles River Labs (CRL) PT, Estimates Raised at Evercore ISI
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Charles River Labs (CRL) PT Raised to $100 at Jefferies
August 4, 2016 10:50 AM EDTJefferies analyst raised his price target on Buy-rated Charles River Labs (NYSE: CRL) to $100.00 (from $94.00) following recent earnings.
commented, "CRL displayed continued strength across all segments. Integration of WIL is underway and should lead to margin leverage from the $17-20M cost synergies. CRL is the pre-clinical CRO "category killer" and continues to drive share gains and revenue growth through comprehensive offerings and a focus on high quality science with benefits to utilization, price, and margin."
The analyst had 4 Key Insights:
1) DSA Outperforms in 1st Quarter with WIL. DSA revenue grew... More
Charles River Laboratories (CRL) Tops Q2 EPS by 10c; Bumps Outlook Higher
August 3, 2016 7:05 AM EDTCharles River Laboratories (NYSE: CRL) reported Q2 EPS of $1.20, $0.10 better than the analyst estimate of $1.10. Revenue for the quarter came in at $434.1 million versus the consensus estimate of $425.08 million.
James C. Foster, Chairman, President and Chief Executive Officer, said, I am very pleased to... More
